Evidence map›Paper›PMID 31941260›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2019

[Observation of the therapeutic and characteristic effects of terlipressin on refractory cirrhotic ascites].

F Xing, S Li, J J Zhang, C Y Sun, J R Huang, Z L Gao, T T Zhu, Q Zhao, H Zhang, C H Liu

Open access · greenAbstract readControlled Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Guideline
  2. [Guidelines on the management of ascites in cirrhosis (2023 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Guideline
  3. Management of Portal Hypertension.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

F XingSecond Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Institute of Liver Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
S LiDepartment of Gastroenterology, Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 201900, China.
J J ZhangDepartment of Integrated Liver Diseases, Zhongshan Hospital of Hubei Province, Wuhan 430033, China.
C Y SunDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
J R HuangDepartment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University, Hangzhou 310003, China.
Z L GaoDepartment of Gastroenterology, Pudong New Area Hospital, Shanghai 201299, China.
T T ZhuSecond Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Institute of Liver Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Q ZhaoSecond Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Institute of Liver Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
H ZhangSecond Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Institute of Liver Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
C H LiuSecond Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Institute of Liver Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China; Shanghai Innovation Center of TCM Health Service, Shanghai 201203, China.
First Affiliated Hospital of Zhengzhou University · CNFirst Affiliated Hospital Zhejiang University · CN

Funding

National Natural Science Foundation of China 81473479
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Acute Kidney InjuryAscitesChildChinaHumansLiver CirrhosisTerlipressinTreatment OutcomeVasoconstrictor AgentsTerlipressinVasoconstrictor AgentsAcute kidney injuryAscitesLiver cirrhosisTerlipressin

Identifiers

PMID31941260
PMCPMC12814613
OpenAlexW3007989420

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.